文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺癌盆腔淋巴结放疗后晚期淋巴细胞减少的骨盆骨髓剂量体积预测因素

Pelvic bone marrow dose-volume predictors of late lymphopenia following pelvic lymph node radiation therapy for prostate cancer.
PubMed 文献 · Radiother Oncol · 2024-03-17

一项前瞻性多中心研究纳入499例接受盆腔淋巴结照射的前列腺癌患者,评估晚期血液学毒性的临床与剂量学预测因素。46例(9.2%)发生2年CTCAEv4.03≥2级淋巴细胞减少,基线淋巴细胞计数、吸烟及腰骶椎骨髓V≥24 Gy(cc)为独立预测因素。作者建议腰骶椎骨髓V24 Gy<307 cc及全骨盆骨髓V10 Gy<1520 cc、V20 Gy<1250 cc、V30 Gy<850 cc的约束可能降低风险。

要点

  • 499例中46例(9.2%)发生2年≥2级淋巴细胞减少(淋巴细胞计数<800/μL)。
  • 基线淋巴细胞计数、吸烟及腰骶椎骨髓V≥24 Gy(cc)为独立预测因素。
  • 作者建议腰骶椎骨髓V24 Gy<307 cc及全骨盆骨髓V10 Gy<1520 cc、V20 Gy<1250 cc、V30 Gy<850 cc的约束。

核心结论

  • 前列腺癌盆腔淋巴结照射后2年淋巴细胞减少主要受基线淋巴细胞计数调节,急性≥3级淋巴细胞减少具有独立作用。
  • 腰骶椎骨髓V24 Gy(cc)是最佳剂量学预测因素,作者建议全骨盆骨髓V10 Gy<1520 cc、V20 Gy<1250 cc、V30 Gy<850 cc及腰骶椎骨髓V24 Gy<307 cc的约束可能降低风险。

研究设计与样本

  • 前瞻性多中心研究,纳入接受盆腔淋巴结照射的前列腺癌患者,前瞻性收集临床、剂量学和血液检测数据。
  • 分析聚焦于2年CTCAEv4.03≥2级淋巴细胞减少(淋巴细胞计数<800/μL),共499例患者数据完整可用。

主要发现

  • 46例患者(9.2%)发生晚期≥2级淋巴细胞减少。
  • 腰骶椎骨髓、下骨盆骨髓、全骨盆骨髓及Body的DVH参数与≥2级淋巴细胞减少增加相关。
  • 多变量模型中保留的变量包括基线淋巴细胞计数(HR=0.997,95%CI 0.996-0.998,p<0.0001)、吸烟(是/否)(HR=2.9,95%CI 1.25-6.76,p=0.013)和腰骶椎骨髓V≥24 Gy(cc)(HR=1.006,95%CI 1.002-1.011,p=0.003)。
  • 当考虑急性≥3级淋巴细胞减少(是/否)时,其被保留在模型中(HR=4.517,95%CI 1.954-10.441,p=0.0004)。
  • 模型性能相对较高(AUC=0.87/0.88),并经内部验证确认。

关键数值与推荐

  • 作者建议全骨盆骨髓约束:V10 Gy<1520 cc、V20 Gy<1250 cc、V30 Gy<850 cc。
  • 作者建议腰骶椎骨髓约束:V24 Gy<307 cc。

临床怎么用

  • 作者建议对全骨盆骨髓V10 Gy<1520 cc、V20 Gy<1250 cc、V30 Gy<850 cc及腰骶椎骨髓V24 Gy<307 cc进行约束,可能降低晚期≥2级淋巴细胞减少风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Given the substantial lack of knowledge, we aimed to assess clinical/dosimetry predictors of late hematological toxicity on patients undergoing pelvic-nodes irradiation (PNI) for prostate cancer (PCa) within a prospective multi-institute study. MATERIALS AND METHODS: Clinical/dosimetry/blood test data were prospectively collected including lymphocytes count (ALC) at baseline, mid/end-PNI, 3/6 months and every 6 months up to 5-year after PNI. DVHs of the Body, ileum (BMILEUM), lumbosacral spine (BMLS), lower pelvis (BMPELVIS), and whole pelvis (BMTOT) were extracted. Current analysis focused on 2-year CTCAEv4.03 Grade ≥ 2 (G2+) lymphopenia (ALC < 800/μL). DVH parameters that better discriminate patients with/without toxicity were first identified. After data pre-processing to limit overfitting, a multi-variable logistic regression model combining DVH and clinical information was identified and internally validated by bootstrap. RESULTS: Complete data of 499 patients were available: 46 patients (9.2 %) experienced late G2+ lymphopenia. DVH parameters of BMLS/BMPELVIS/BMTOT and Body were associated to increased G2+ lymphopenia. The variables retained in the resulting model were ALC at baseline [HR = 0.997, 95 %CI 0.996-0.998, p < 0.0001], smoke (yes/no) [HR = 2.9, 95 %CI 1.25-6.76, p = 0.013] and BMLS-V ≥ 24 Gy (cc) [HR = 1.006, 95 %CI 1.002-1.011, p = 0.003]. When acute G3+ lymphopenia (yes/no) was considered, it was retained in the model [HR = 4.517, 95 %CI 1.954-10.441, p = 0.0004]. Performances of the models were relatively high (AUC = 0.87/0.88) and confirmed by validation. CONCLUSIONS: Two-year lymphopenia after PNI for PCa is largely modulated by baseline ALC, with an independent role of acute G3+ lymphopenia. BMLS-V24 was the best dosimetry predictor: constraints for BMTOT (V10Gy < 1520 cc, V20Gy < 1250 cc, V30Gy < 850 cc), and BMLS (V24y < 307 cc) were suggested to potentially reduce the risk.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Pavarini M, Alborghetti L, Aimonetto S, et al. Pelvic bone marrow dose-volume predictors of late lymphopenia following pelvic lymph node radiation therapy for prostate cancer. Radiother Oncol. 2024. PMID: 38503355. doi:10.1016/j.radonc.2024.110230

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。